摘要 : Background: Fluoropyrimidine chemotherapy is used across many tumor types and settings. The incidence of severe adverse events (SAEs) is around 20%. Mortality is 0.5%-1%. Dihydropyrimidine dehydrogenase (DPD) plays a key role in f... 展开
作者 | Wang~ Lei Howlett~ Sarah Essapen~ Sharadah |
---|---|
作者单位 | |
期刊名称 | 《Seminars in Oncology》 |
总页数 | 8 |
语种/中图分类号 | 英语 / R73 |
关键词 | DPYD Fluoropyrimidine Chemotherapy Drug safety Toxicity CLINICAL PHARMACOKINETICS DPYD GENOTYPE 5-FLUOROURACIL CAPECITABINE PREVENTION TOXICITY CANCER |
馆藏号 | N2007EPST0001132 |